Oncology Learning Center | Personalized Therapies for Lung, Breast, Colorectal, Hematology, Cancer

>> Login

>> New User Registration

September 9, 2010

Overview

Disclosure

Faculty

Agenda

Hotel Accommodations

Registration

Co-Chairs

Dr. Bunn
Paul A. Bunn, Jr., MD
James Dudley Chair in Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Aurora, CO
Executive Director, International Association for the Study of Lung Cancer
(IASLC)

Dr. Bunn
Roy S. Herbst, MD, PhD
Chief, Section of Thoracic Oncology
Professor of Medicine & Cancer Biology
Department of Thoracic / Head & Neck Medical Oncology
Co-Director, Phase I Clinical Trials Working Group
The University of Texas
M. D. Anderson Cancer Center
Houston, TX

Dr. Bunn
Corey J. Langer, MD
Professor of Medicine
Director, Thoracic Oncology
Division of Hematology-Oncology
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
Vice Chair, Radiation Therapy Oncology Group
(RTOG)

Other Expert Faculty

Dr. Burtness
Barbara Burtness, MD
Chief, Head and Neck Medical Oncology
Department of Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

Dr. Curran
Walter J. Curran, MD, FACR
Professor and Chair
Department of Radiation Oncology
Emory School of Medicine Chief Medical Officer
Winship Cancer Institute
Atlanta, GA
Chairman, Radiation Therapy Oncology Group
(RTOG)

Dr. Heymach
John V. Heymach, MD, PhD
Assistant Professor of Thoracic Head/Neck Medical Oncology
Assistant Professor of Cancer Biology
The University of Texas
M. D. Anderson Cancer Center
Houston, TX

Dr. Kris
Mark G. Kris, MD
Chief, Thoracic Oncology Service
The William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Medical College of Cornell University
New York NY

Dr. Ladanyi
Marc Ladanyi, MD
Chief, Molecular Diagnostics Service
Department of Pathology
Member, Human Oncology and Pathogenesis Program
Memorial Sloan-Kettering Cancer Center
Attending Pathologist
New York, NY

Dr. Lynch
Thomas J. Lynch, Jr., MD
Director, Yale Cancer Center
Physician-in-Chief,
Smilow Cancer Hospital, Yale-New Haven
New Haven, CT

Dr. Miller
Vincent A. Miller, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
New York, NY

Dr. Sandler
Alan B. Sandler, MD
Professor of Medicine
Division Chief, Hematology & Medical Oncology
DeArmond Chair, Clinical Cancer Research
Oregon Health & Science University
Portland, OR
Co-Chair, Eastern Cooperative Oncology Group
(ECOG)

Dr. Schiller
Joan H. Schiller, MD
Professor & Division Chief,
Hematology-Oncology
Deputy Director, Harold C. Simmons Cancer Center
Andrea L. Simons Distinguished Chair in Cancer Research
UT Southwestern Medical Center
Dallas, TX
Chair, Lung Committee, Eastern Cooperative Oncology Group
(ECOG)

Dr. Simon
George R. Simon, MD, FACP, FCCP
Director, Thoracic Oncology Program
Department of Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

September 26, 2009 · Philadelphia, PA

Sheraton Philadelphia City Center Hotel

Taught by the top academic experts in lung cancer and head and neck cancer this is THE symposium on thoracic malignancies that you should attend in 2009. It contains the relevant data from the recent ASCO and the World Lung Cancer Congress. Personalized medicine for treating thoracic malignancies is a reality. This symposium will help clinicians improve their selection of the most appropriate therapeutics, and will also help clinicians to identify the patient sub-populations of lung cancer and head and neck cancer who will respond to specific drug therapies.

CO-CHAIRS

Paul A. Bunn, Jr., MD
James Dudley Chair in Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Aurora, CO
Executive Director,
International Association for the Study of Lung Cancer
(IASLC)

Roy S. Herbst, MD, PhD
Chief, Section of Thoracic Oncology
Professor of Medicine & Cancer Biology
Department of Thoracic / Head & Neck Medical Oncology
Co-Director, Phase I Clinical Trials Working Group
The University of Texas, M. D. Anderson Cancer Center
Houston, TX

Corey J. Langer, MD
Professor of Medicine
Director, Thoracic Oncology
Division of Hematology-Oncology
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
Vice Chair, Radiation Therapy Oncology Group
(RTOG)


•	Overview
•	Educational Statement of Need
•	Disclosure
•	Target Audience
•	Learning Objectives
•	CME Credit Information
•	Methods of Participation
•	Agenda
•	Faculty
•	Sheraton Hotel
•	Registration

Agenda

Second Annual Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
September 25, 2008 – Friday
5:00PM – 9:00PM	Early Registration

September 26, 2008 – Saturday
7:00AM – 8:00AM	Buffet Breakfast
7:00AM – 8:00AM	Registration
8:00AM – 8:05AM	Welcome and Introductions	Paul Bunn(Co-Chair) Roy Herbst(Co-Chair) Corey Langer (Co-Chair)
8:05AM – 8:10AM	CME Pre Test	Roy Herbst

Session 1: Personalizing Chemotherapy and Best Clinical Practices – Paul Bunn (Session Chair)

8:10AM – 8:20AM	Current best clinical practices using systemic therapy for treating thoracic malignancies. Have personalized regimens of chemotherapies and targeted therapies achieved what they should have?	Paul Bunn
8:20AM – 8:40AM	Personalizing chemotherapy for lung cancer	George Simon
8:40AM – 9:00AM	Studies of molecular markers to personalize head and neck cancer therapy	Barbara Burtness
9:00AM – 9:20AM	The clinical applications of maintenance chemotherapy for NSCLC	Corey Langer
9:20AM – 9:40AM	New clinical applications of chemotherapy plus radiation for thoracic malignancies. Can this combined-modality approach be personalized?	Walter Curran
9:40AM – 10:00AM	BREAK
10:00AM – 10:15AM	Novel agents and new treatment strategies for SCLC	Joan Schiller
10:15AM – 10:30AM	Point Counterpoint #1: We have reached the maximum benefits with chemotherapy for treating thoracic malignancies.	PRO Thomas Lynch CON George Simon
10:30AM – 10:45AM	Session 1 Case Study - Using ARS and learners selecting treatment options; best clinical practices for first-line, maintenance therapy and salvage therapy with chemotherapy	George Simon
10:45AM – 11:00AM	Panel Discussion, Q&A and Consensus on the Status of the Data Presented in this Session: 1. Is any of this a new standard of care? 2. Should it be discussed with your patients? 3. How can it be applied in the clinic today?	Session 1 Faculty and Participants 1. Each faculty addresses all three questions

Session 2: Personalizing Anti-Angiogenesis Therapy and Best Clinical Practices – Joan Schiller (Session Chair)

11:00AM – 11:20AM	Personalizing therapies for thoracic malignancies with anti-angiogenesis small molecules	Roy Herbst
11:20AM – 11:40AM	Personalizing therapies for thoracic malignancies with anti-VEGF monoclonal antibodies against the receptor and against the ligand	Alan Sandler
11:40AM– 12:30PM	LUNCH with the Professors: Each of the day’s faculty will be assigned a separate lunch table so that the symposium participants can further interact with a faculty member on his/her presentation or topic.	Participants and Faculty
12:30PM – 12:50PM	Using molecular biomarkers for devising personalized therapy strategies with anti-angiogenic agents for thoracic malignancies	John Heymach
12:50PM – 1:10PM	Dual targeting strategies utilizing anti-angiogenic and anti-EGFR agents in combination therapy as multi-targeted agents	Vince Miller
1:10PM – 1:30PM	Can we personalize the combination of anti-angiogenesis systemic therapy plus radiation and also with anti-EGFR systemic therapy plus radiation?	Walter Curran
1:30PM – 1:45PM	Point Counterpoint #2: Chemotherapy plus an anti-VEGF monoclonal antibody is a standard of care for patients eligible for this regimen.	PRO Alan Sandler CON Mark Kris
1:45PM – 2:00PM	Session 2 Case Study - Using ARS and learners selecting treatment options; best clinical practices for first-line, maintenance therapy and salvage therapy with anti-angiogenesis agents	Joan Schiller
2:00PM – 2:15PM	Panel Discussion, Q&A and Consensus on the Status of the Data Presented in this Session: 1. Is any of this a new standard of care? 2. Should it be discussed with your patients? 3. How can it be applied in the clinic today?	Session 2 Faculty and Participants 1. Each faculty addresses all three questions

Session 3: Personalizing Anti-EGFR Therapy and Best Clinical Practices – Thomas Lynch (Session Chair)

2:15PM – 2:35PM	Personalizing therapies for thoracic malignancies with anti-EGFR treatment strategies	Thomas Lynch
2:35PM – 2:55PM	Developing treatment strategies for managing inherent and acquired resistance to anti-EGFR therapy for NSCLC in both wild type and EGFR mutant patients	Mark Kris
2:55PM – 3:10PM	BREAK
3:10PM – 3:20PM	EGFR and KRAS testing: new roles for pathology and molecular diagnostics	Marc Ladanyi
3:20PM – 3:40PM	Panel Discussion and Q & A: Audience asks faculty about the value and clinical application of any commercially available diagnostic test for NSCLC or HNC that may or may not be yet validated with a prospective clinical trial	Discussant Leader: Paul Bunn Faculty and Participants
3:40PM – 4:00PM	Anti-EGFR treatment strategies in the maintenance setting for patients with NSCLC	Vince Miller
4:00PM – 4:20PM	Point Counterpoint #3: All patients with receiving an anti-EGFR therapy for thoracic malignancies should be screened for the EGFR mutation.	PRO: Mark Kris CON: Corey Langer
4:20PM – 4:35PM	Session 3 Two Case Studies: Using ARS and learners selecting treatment options; best clinical practices for first-line, maintenance therapy and salvage therapy with anti-EGFR agents; and a NSCLC patient on a small molecule anti-EGFR tki for 1 year then slowly progresses.	Paul Bunn
4:35PM – 4:50PM	Panel Discussion, Q&A and Consensus on the Status of the Data Presented in this Session: 1. Is any of this a new standard of care? 2. Should it be discussed with your patients? 3. How can it be applied in the clinic today?	Session 3 Faculty and Participants 1. Each faculty addresses all three questions

Session 4: Investigational Agents for Lung Cancer – Roy Herbst (Session Chair)

4:50PM – 5:10PM	Investigational Drugs In Late Stage Development for Lung Cancer	Roy Herbst
5:10PM – 5:20PM	Q & A and Discussion	Faculty and Audience
5:20PM – 5:25PM	Meeting Conclusions and CME Post Test	Paul Bunn

Educational Grants

Sincere appreciation is extended to the following companies for their generous support of this educational meeting: